Eris Lifesciences Limited (NSE:ERIS)
India · Delayed Price · Currency is INR | Market Cap | 190.29B +1.8% |
| Revenue (ttm) | 30.65B +12.5% |
| Net Income | 4.31B +30.9% |
| EPS | 31.63 +30.8% |
| Shares Out | 138.54M |
| PE Ratio | 43.43 |
| Forward PE | 29.39 |
| Dividend | 7.35 (0.54%) |
| Ex-Dividend Date | n/a |
| Volume | 252,849 |
| Average Volume | 129,201 |
| Open | 1,353.00 |
| Previous Close | 1,373.50 |
| Day's Range | 1,341.10 - 1,393.80 |
| 52-Week Range | 1,236.00 - 1,910.00 |
| Beta | -0.14 |
| RSI | 50.43 |
| Earnings Date | May 19, 2026 |
About Eris Lifesciences
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electro... [Read more]
Financial Performance
In fiscal year 2025, Eris Lifesciences's revenue was 28.79 billion, an increase of 44.59% compared to the previous year's 19.91 billion. Earnings were 3.52 billion, a decrease of -10.26%.
Financial StatementsNews
Eris Lifesciences faces procedural non-compliance at Swiss Parenterals units
Eris Lifesciences has announced that its Swiss Parenterals Units 1 and 2 in Ahmedabad, Gujarat, have been inspected by HALMED, the Agency for Medicinal Products and Medical Devices of Croatia,…
Eris Lifesciences completes acquisition of Velbiom Probiotics business
Eris Lifesciences has successfully completed the acquisition of the probiotics business from Velbiom Probiotics Private Limited. This marks the closure of a transaction initially announced on 20 March...
Eris Lifesciences partners with Natco Pharma for semaglutide launch in India
Eris Lifesciences Limited has announced a strategic partnership with Natco Pharma Limited to commercialise Semaglutide in India. This move aims to bolster Eris's leadership in the rapidly expanding di...
Eris Lifesciences partners with Natco Pharma to launch Semaglutide in India
Eris Lifesciences Limited has entered into a strategic partnership with Natco Pharma Limited for the commercialisation of semaglutide in India,...
Eris Lifesciences Ltd (NSE:ERIS) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...
Eris Lifesciences Ltd (NSE:ERIS) Q3 2026 Earnings Call Highlights: Strong Revenue Growth Amid Margin Challenges
Q3 2026 Eris Lifesciences Ltd Earnings Call Transcript
Q3 2026 Eris Lifesciences Ltd Earnings Call Transcript
Eris Lifesciences Transcript: Q3 25/26
Q3 and nine-month results showed double-digit growth in revenue and profits, with strong performance in branded formulations and international business. Margin expansion, new product launches, and a robust CDMO order book support a positive outlook, while CapEx is being front-loaded for strategic growth.
Eris Lifesciences Q3 Results: Revenue jumps 10% YoY to Rs 807 crore, net profit up 19%
Eris Lifesciences reported a steady set of numbers for the third quarter, with profit and operating performance showing year-on-year growth....
Eris Lifesciences Ltd (NSE:ERIS) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Eris Lifesciences Ltd (NSE:ERIS) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Q2 2026 Eris Lifesciences Ltd Earnings Call Transcript
Q2 2026 Eris Lifesciences Ltd Earnings Call Transcript
Eris Lifesciences Transcript: Q2 25/26
Q2 saw 10% domestic revenue growth and 11% EBITDA growth, with Biocon margins rising to 32%. International business expanded, and the European CDMO order book reached INR 700-800 crore. CapEx is front-loaded, with net debt-to-EBITDA expected below 1.5x by Dec 2026.
Eris Lifesciences Q2 Results: Net profit jumps 31% YoY to Rs 120 crore, revenue up 6.3%
Eris Lifesciences Limited reported a strong performance for the second quarter of FY26, with a healthy rise in profitability and...
Eris Lifesciences secures ANVISA approval for Ahmedabad sterile injectable facility
Eris Lifesciences Limited on Tuesday announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from ANVISA, Brazil’s national health regulatory agency. T...
Eris Lifesciences secures approval from ANVISA for Ahmedabad facility
Eris Lifesciences Limited (BSE: 540596, NSE: ERIS), one of India’s leading branded formulations companies, announced that a manufacturing unit at its Ahmedabad campus has received approval from ANVISA...
Eris Lifesciences shares plunge nearly 5% today despite 41% jump in Q1 net profit
Shares of Eris Lifesciences Ltd declined nearly 5% to ₹1,727 in early trade on Wednesday, August 6, even after the company posted a strong 41% year-on-year rise in consolidated net profit to ₹125 cror...
Eris Lifesciences Transcript: Q1 25/26
DBF segment delivered 11% revenue growth and 37% EBITDA margin, while consolidated profit after tax rose 41% year-on-year. Insulin and GLP-1 capacity expansions are on track, and the international business is pivoting to higher-margin EU markets with confirmed CDMO contracts.
Eris Lifesciences Q1 Results: Net profit jump 41.7% YoY to Rs 118 crore, revenue up 7.8% YoY
Eris Lifesciences Ltd. has posted a strong set of numbers for the quarter ended June 30, 2025, reflecting continued momentum in its core operations. The company reported consolidated revenue from oper...
Eris Lifesciences shares jump 3% as Q4 EBITDA rises 69.8% YoY to 252.2 crore
Shares of Eris Lifesciences rose by around 3% in early trade following the release of the company’s fourth-quarter earnings report. The pharmaceutical company posted a year-on-year increase in its net...
Eris Lifesciences Transcript: Q4 24/25
Q4 revenue grew 28% year-on-year to INR 705 crores, with EBITDA up 70% and strong margin expansion. FY 2025 saw robust growth in DBF and Swiss Parenterals, improved ROCE, and significant debt reduction, with FY 2026 guidance projecting continued double-digit growth and margin improvement.
Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report
Shares of Eris Lifesciences, Lupin, and Biocon were in focus on April 23 after pharmaceutical major Novo Nordisk announced the discontinuation of its Human Mixtard insulin brand in India — one of the ...
Eris Lifesciences shares surge over 4% as Novo Nordisk reportedly exits Human Mixtard insulin market in India
Shares of Eris Lifesciences Ltd climbed 4.19% to ₹1,458 in early trade on April 23 after Novo Nordisk reportedly announced its decision to phase out Human Mixtard—India’s largest-selling insulin brand...
Eris Lifesciences Transcript: Q3 24/25
Q3 and YTD saw strong revenue and EBITDA growth, with margins expanding and debt reduction ahead of schedule. Strategic investments in biologics and new product launches are set to drive future growth, with a major GLP-1 market entry planned for 2026.
Eris Lifesciences shares drop 4% as net profit dips 14.3% YoY in Q3
Eris Lifesciences shares declined by 4% after the company announced its Q3 FY25 financial results. Despite strong revenue growth, profitability took a hit due to rising expenses. As of 1:04 AM, the sh...
Eris Lifesciences Q3 FY25 Results: Revenue up 49.6% YoY to Rs 727.45 crore, Net profit dips 14.3%
Eris Lifesciences reported its Q3 FY25 financial results, showcasing strong revenue growth but a decline in net profit due to higher expenses. The company’s revenue from operations surged to ₹727.45 c...
Eris Lifesciences Transcript: Q2 24/25
Q2 revenue grew 47% year-over-year to INR 741 crores, with EBITDA up 46% and margins stable. Integration of acquisitions and manufacturing improvements drove margin expansion and cost synergies. Guidance for FY 2025 is reaffirmed, with new product launches and strategic investments set to support future growth.